Trident Lifeline

Trident Lifeline EBITDA per Employee

Delisted·Sep 16, 2026

The EBITDA per Employee of Trident Lifeline (543616.BO) as of Oct 31, 2026 is 4.13 M INR. In the previous year, EBITDA per Employee was 2.28 M INR — a change of 81.44% (higher).

EBITDA per Employee

4.13 MINR

YoY

81.44%

Last updated:

EBITDA per Employee of Trident Lifeline is 2025 4.13 M INR. EBITDA per Employee of Trident Lifeline was 2024 2.28 M INR. It decreases by 81.44% higher compared to the previous year.

The Trident Lifeline EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2021
345,333.33 INR
Jan 1, 2022
752,333.33 INR
Jan 1, 2023
1.74 M INR
Jan 1, 2024
2.28 M INR
Jan 1, 2025
4.13 M INR
The Trident Lifeline EBITDA per Employee history
YEAREBITDA per EmployeeYoY
4.13 MINR+81.44%
2.28 MINR+31.03%
1.74 MINR+130.79%
752,333.33INR+117.86%
345,333.33INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Trident Lifeline Stock analysis

What does Trident Lifeline do? Trident Lifeline Ltd. generates revenue through the manufacturing and marketing of pharmaceutical products across seven geographical segments including India, Ghana, Kenya, Nigeria, Cameroon, Venezuela, and Rest of World. The company produces a diverse range of pharmaceutical formulations such as capsules, tablets, liquid ointments, gels, mouthwashes, and toothpaste under contract manufacturing on loan license. Its product portfolio features drugs like Anti-Bacterial, Anti Diarrheal, Anti-Fungal, Anti-Malarial, Anti Diabetic, Dental Cure, Proton Pump Inhibitor, Anti Protozoal, Anti Histamine, Anti-Hypertensive, Anti Lipidemic, Anti Parasitic, Multivitamin, Multimineral, Nutraceutical, and Non-Steroidal Anti-Inflammatory Drug (NSAIDS). The primary buyers are healthcare providers and consumers in the pharmaceutical market, with a focus on both domestic and international markets. The company's revenue streams are derived from the sale of its extensive product range, which includes both prescription and over-the-counter medications. By operating through multiple geographical segments, Trident Lifeline Ltd. caters to a broad customer base across different regions, ensuring consistent demand for its pharmaceutical formulations. The contract manufacturing model under loan license allows the company to leverage partnerships without significant capital investment, optimizing production costs and scalability. Trident Lifeline Ltd. targets healthcare providers and consumers seeking affordable pharmaceutical solutions, particularly in emerging markets. Its product offerings address a wide spectrum of health needs, from common ailments like diarrhea and fungal infections to chronic conditions such as diabetes and hypertension. This strategic focus on diverse drug categories ensures steady demand across its operational segments, supporting sustainable revenue growth. Trident Lifeline is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Trident Lifeline stock

EBITDA per Employee of Trident Lifeline is 4.13 M INR in 2025.

EBITDA per Employee of Trident Lifeline changed from 2.28 M INR to 4.13 M INR, representing a 81.44% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee Trident Lifeline since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Trident Lifeline historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Trident Lifeline

All Key Metrics — Trident Lifeline